OPSMILL
28.5.2024 12:01:28 CEST | Business Wire | Press release
OpsMill, a pioneer in infrastructure and network automation, today announced the beta release of its open source Infrahub platform. Infrahub unifies previously disparate automation capabilities into a single platform, enabling IT teams to transform all their data center, cloud, network, and security infrastructure operations with scalable and consumable automation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240528726475/en/
Infrahub brings the worlds of infrastructure-as-code and infrastructure management together in a single platform (Graphic: Business Wire)
“I’ve spent years building automation systems for infrastructure and network management across a variety of organizations. At every stop, I encountered the same challenges: Managing network and cloud infrastructure required the use of a confusing, cumbersome, costly mix of solutions. These tools were always hampered by serious technical limitations, such as inflexible data models,” said Damien Garros, CEO and co-Founder, OpsMill. “With the release of Infrahub’s open beta, we’ve drawn on years of experience to solve those challenges. This is the first platform that unites the GitOps Infrastructure-as-Code approach with an extensible structured data model. By combining these two approaches, Infrahub frees infrastructure and automation teams from having to integrate and maintain a fragile set of tools. Instead, they can focus on driving innovation through better automation.”
Infrastructure automation has suffered from an unhelpful divide between GitOps and traditional infrastructure management approaches that prevents teams from gaining the critical advantages and best practices of both approaches. GitOps, an automation approach used by many software development teams, offers version control and continuous integration (CI) validation, which are critical for maintaining an accurate data model while scaling automation use. However, GitOps doesn’t offer a structured data model that most easily represents IT infrastructure components and their many inter-linkages. Traditional infrastructure management approaches offer infrastructure-friendly structured databases, but don’t include version control or CI, and are constrained by fixed data models that limit their flexibility.
Infrahub unifies the best of both worlds in a single platform, including the following key capabilities:
- Extensible Graph Database: Infrahub overcomes the limitations of source-of-truth databases that come with fixed schemas. It is built on an extensible, knowledge-graph database that is ideal for representing and querying the many interrelationships between infrastructure components. Infrahub’s flexible data model means that it can scale across data centers, clouds, networks, and security infrastructure and use cases.
- Version Control: Infrahub makes versioning possible for your entire data model and all the data populated into that model. This means that multiple members of your team can, in parallel, create a branch of the entire infrastructure database, update an infrastructure component in the database in order to generate configuration files for a network change, then merge the updates back into the database. Native versioning of a centralized and extensible infrastructure database is a key innovation of Infrahub.
- Artifact Rendering: Infrahub doesn’t leave you alone in managing the generation of artifacts such as configuration files or reporting data files. It includes native artifact rendering as a native platform capability.
- Continuous Integration (CI): Infrahub has built in the process for performing CI validations to ensure quality control over configuration and data changes.
“As someone who has engineered large backbone networks and helped build a company that relied on extensive network and cloud infrastructure, I’ve seen firsthand how much organizations struggle with scalable and maintainable automation,” said Raphael Maunier, COO and co-Founder, OpsMill. “Infrastructure teams often need their own dev teams just to gather data and build infrastructure, leading to high maintenance costs and slowed innovation. OpsMill was founded to change this. Infrahub provides all the key elements for scalable infrastructure and network automation success, allowing teams to focus on innovation instead of maintaining custom software.”
The open beta version of Infrahub is available now. Visit GitHub to get started today.
About OpsMill
OpsMill is the infrastructure automation platform company, bringing the best practices and features of the industry’s leading automation approaches together in a single, scalable, and extensible platform so that infrastructure, cloud, network, and security teams can focus on innovation rather than integrating toolsets. Infrahub by OpsMill is the industry’s leading open-source integrated infrastructure automation platform. OpsMill is backed by Serena Capital, Partech, OVNI Capital, Kima Ventures and Better Angle. For more information, visit OpsMill.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240528726475/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
